



EP12

Evaluation of Qualitative, Binary Output Examination Performance

This guideline includes descriptions of the types of qualitative, binary output examinations and procedures for evaluating their performance.

.....
A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.

Clinical and Laboratory Standards Institute

Setting the standard for quality in medical laboratory testing around the world.

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing medical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advances in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential and may be submitted by anyone, at any time, on any document. All comments are managed according to the consensus process by a committee of experts.

Appeal Process

When it is believed that an objection has not been adequately considered and responded to, the process for appeal, documented in the *CLSI Standards Development Policies and Processes*, is followed.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For additional information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute

P: +1.610.688.0100

F: +1.610.688.0700

www.clsi.org

standard@clsi.org

Evaluation of Qualitative, Binary Output Examination Performance

Jeffrey R. Budd, PhD
Karl De Vore, BA, SSBB
Ralf C. Bollhagen, PhD
Abdel-Baset Halim, PharmD, PhD, DABCC
Paul S. Horn, PhD

Marina V. Kondratovich, PhD
Qin Li, PhD
Kristen Meier, PhD
Gene Pennello, PhD
Diane M. Ward, PhD

Abstract

Clinical and Laboratory Standards Institute guideline EP12—*Evaluation of Qualitative, Binary Output Examination Performance* describes the categories of qualitative, binary output examinations and covers their performance evaluations for imprecision, including estimating C5 and C95, clinical performance (sensitivity and specificity), and stability and interferences.

Clinical and Laboratory Standards Institute (CLSI). *Evaluation of Qualitative, Binary Output Examination Performance*. 3rd ed. CLSI guideline EP12 (ISBN 978-1-68440-176-5 [Print]; ISBN 978-1-68440-177-2 [Electronic]). Clinical and Laboratory Standards Institute, USA, 2023.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at www.clsi.org.

If you or your organization is not a member and would like to become one, or to request a copy of the catalog, contact us at:

P: +1.610.688.0100 **F:** +1.610.688.0700 **E:** customerservice@clsi.org **W:** www.clsi.org

Copyright ©2023 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, derivative product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to permissions@clsi.org.

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedures manual at a single site. To request permission to use this publication in any other manner, e-mail permissions@clsi.org.

Suggested Citation

CLSI. *Evaluation of Qualitative, Binary Output Examination Performance*. 3rd ed. CLSI guideline EP12. Clinical and Laboratory Standards Institute; 2023.

Previous Editions:

August 2002, January 2008

EP12-Ed3

ISBN 978-1-68440-176-5 (Print)

ISBN 978-1-68440-177-2 (Electronic)

ISSN 1558-6502 (Print)

ISSN 2162-2914 (Electronic)

Volume 43, Number 4

Committee Membership

Consensus Council

The Consensus Council sets priorities for CLSI standards development and votes on Final Draft documents to confirm that process requirements have been met. Consensus Council members are listed on the CLSI website: <https://clsi.org/standards-development/consensus-council/>

Document Development Committee on Establishment and Verification of Qualitative Measurement Procedures for Performance

Jeffrey R. Budd, PhD

Chairholder

USA

Abdel-Baset Halim, PharmD, PhD,
DABCC
Celldex Therapeutics Taiho Oncology
USA

USA

Kristen Meier, PhD

Illumina Inc.

USA

Karl De Vore, BA, SSBB

Vice-Chairholder

Bio-Rad Laboratories, Inc.

USA

Paul S. Horn, PhD
Divisions of Neurology and
Biostatistics & Epidemiology
USA

Diane M. Ward, PhD

Qserve Group US, Inc.

USA

Ralf C. Bollhagen, PhD
Roche Diagnostics GmbH
Germany

Qin Li, PhD
FDA Center for Devices and
Radiological Health

Expert Panel on Evaluation Protocols

Expert panel volunteers support the development of CLSI documents by providing technical expertise in specialty areas. Expert panel members are listed by area of expertise on the CLSI website: <https://clsi.org/standards-development/expert-panels/>

Staff

Clinical and Laboratory Standards
Institute
USA

Shirley Martin
Editorial Manager

Kristy L. Leirer, MS
Editor

Tabitha Kern, MS, MLS(ASCP)[®]
Program Manager

Catherine E.M. Jenkins, ELS
Editor

Lisa M.W. Walker, MS, ELS
Editor

Acknowledgment

CLSI, the Consensus Council, and the Document Development Committee on Establishment and Verification of Qualitative Measurement Procedure Performance gratefully acknowledge the following volunteers for their important contributions to the revision of this guideline:

Marina V. Kondratovich, PhD
FDA Center for Devices and
Radiological Health
USA

Bernard J. Rice, BS
bioMérieux, Inc.
USA

Jeffrey E. Vaks, PhD
Roche Molecular Diagnostics
USA

Gene Pennello, PhD
FDA Center for Devices and
Radiological Health
USA

Currently in preview, click buy full version

Contents

Abstract	i
Committee Membership	iii
Foreword	vii
Chapter 1: Introduction	1
1.1 Scope	1
1.2 Background	2
1.3 Standard Precautions	2
1.4 Terminology	3
Chapter 2: Qualitative Examinations	11
2.1 Qualitative and Grouping Parameters	12
2.2 Subcategories of Qualitative, Binary Output Examinations	13
Chapter 3: Developing a Qualitative, Binary Output Examination	15
3.1 Developing Qualitative Examinations Using a Cutoff Comparison With an Internal Continuous Response	16
3.2 Developing Analyte-Detection, Qualitative Examinations	25
3.3 Control Materials	30
3.4 Determining Stability of Reagent Materials Used in Qualitative Examinations	31
Chapter 4: Validating a Qualitative, Binary Output Examination	33
4.1 Precision Studies	34
4.2 Clinical Performance Evaluation	41
4.3 Interfering Substances Testing for Qualitative Examinations	53
4.4 Sample Selection for Interfering Substances Testing	53
4.5 Reporting Performance Claims	54
Chapter 5: Laboratory Verification of Performance Claims	55
5.1 Verification of Precision	56
5.2 Clinical Performance or Agreement	59
5.3 Reagent Stability Study	61
5.4 Reagent Lot Changes	62

Contents (Continued)

Chapter 6: Conclusion	63
Chapter 7: Supplemental Information	65
References	66
Additional Resources	70
Appendix A. Examination Examples	71
Appendix B. Link Between Distribution of Internal Continuous Response and Probit or Logit Models	73
Appendix C. Visually Read, Qualitative, Binary Examinations	78
Appendix D. Next-Generation Sequencing Precision Evaluation	81
Appendix E. Determining Lower Limit of Detection for Analyte-Detection, Qualitative Examinations Based on Polymerase Chain Reaction Methods	92
Appendix F. Precision Study Designs	96
Appendix G. Observer Precision Studies	100
Appendix H. Wilson Score Method for Calculating Confidence Intervals	104
Appendix I. Clinical Performance Analysis Examples	110
Appendix J. Real-Time Polymerase Chain Reaction Example for Vancomycin-Resistant Enterococci	123
The Quality Management System Approach	128

Foreword

In vitro diagnostic (IVD) examinations report either the value or the characteristics of a clinical property. Quantitative examinations (measurement procedures) measure and report the value of a property of clinical samples. Other examinations of clinical samples report characteristics of a property by placing them into two binary categories: unordered (nominal) and ordered (ordinal). This guideline covers qualitative examinations that, in the user's hands, provide binary (eg, yes or no, positive or negative), nominal outputs (see Appendix A for examples). These examinations span a wide range of medical laboratory specialties, medical purposes, measurement technologies, and types of reported results. A binary response is created based on:

- A device's internal continuous response and a cutoff to provide binary results
- Algorithmic decision-making techniques that detect whether an analyte is present
- In some cases, a yes or no output without the aid of instrumentation

The performance of an IVD examination should be assessed during and after its development, and its performance should be validated before any examination results are used to make clinical decisions. This guideline covers the development of qualitative, binary, results-reporting or output examinations (referred to as qualitative, binary examinations throughout) and is intended to promote uniformity in performance assessment among:

- Developers of qualitative, binary examinations for:
 - Designing and developing examinations
 - Establishing and validating examination performance based on how an examination is designed
- Laboratories that verify qualitative, binary examinations before they are placed into service
- Laboratories that develop their own qualitative, binary examination(s)

Many quantitative examinations provide measurand values in units plus a decision threshold that can be applied to obtain a binary interpretation (see examination examples in Appendix A). Although the binary output performance of these examinations can be determined using the methods described in this guideline, performance evaluations designed for quantitative methods provide more flexibility and have more power to detect differences in performance. Therefore, performance assessment of quantitative examinations should be based on the guidelines described in CLSI document EP19.¹

Overview of Changes

This guideline replaces the previous edition of the approved guideline, EP12-A2, published in 2008. Several changes were made in this edition, including:

- Expanding the types of procedures covered to reflect ongoing advances in laboratory medicine
- Adding protocols to be used by developers, including commercial manufacturers or medical laboratories, during examination procedure design as well as for validation and verification
- Adding topics such as stability and interferences to the existing coverage of the assessment of precision and clinical performance (or examination agreement)
- Moving most of the statistical details, including equations, to the appendixes

NOTE: The content of this guideline is supported by the CLSI consensus process and does not necessarily reflect the views of any single individual or organization.

KEY WORDS

binary reporting

negative likelihood ratio

precision

clinical sensitivity

negative predictive value

qualitative examination

clinical specificity

positive likelihood ratio

stability

interferences

positive predictive value

Chapter ①

Introduction

Evaluation of Qualitative, Binary Output Examination Performance

1 Introduction

1.1 Scope

EP12 provides product design guidance and protocols for performance evaluation of the Establishment and Implementation Stages of the Test Life Phases Model of examinations (see CLSI document EP19¹). EP12 characterizes a target condition (TC) with only two possible outputs (eg, positive or negative, present or absent, reactive or nonreactive). EP12 is written for both manufacturers of qualitative, binary, results-reporting or output examinations (referred to as qualitative, binary examinations throughout) and medical laboratories that create laboratory-developed, binary examinations (both termed developers). These protocols are also intended to help users verify examination performance in their own testing environment. Performance evaluation of examinations that provide outputs with more than two possible categories in an unordered (nominal) set or that report ordinal categories are outside the scope of this guideline.

1.2 Background

It is often necessary to provide test method results that have binary outputs (eg, yes or no). Health care providers may want to order an examination to help determine whether a disease is present in a patient, an analyte is present in a sample, a woman is pregnant, or the results of a drug test are positive. The two primary evaluations used for such examinations are clinical performance (sensitivity and specificity) and precision.

Assessments of clinical performance during the establishment and validation of a binary categorization process are performed by examining samples from subjects with a known category (ie, TC present vs TC absent). Ideally this analysis involves the comparison of binary results for an intended-use population of samples from the candidate examination with an independent procedure that provides the best available assessment of TC. However, in many cases, this comparison of binary results is an evaluation of agreement to positive or negative results from a comparative examination that is not such an assessment procedure.

Qualitative examination determinants of imprecision depend on the idea of the values in a relevant scale where a binary examination declares a sample to be positive 5% of the time (C5) and 95% of the time (C95). Unlike clinical performance, the means of determining C5 and C95 are different depending on how the binary categorization is performed (see Subchapters 3.1.3 and 3.2).

Reagent stability and examination interferences are two other performance attributes of examination systems. Although both topics are covered in CLSI documents EP07² (interferences) and EP25³ (stability), there are several considerations unique to qualitative examinations that warrant additional coverage in EP12. See Subchapters 3.4 (stability) and 4.3 (interferences) for more information on these topics.

1.3 Standard Precautions

Because it is often impossible to know what isolates or specimens might be infectious, all patient and laboratory specimens are treated as infectious and handled according to “standard precautions.” Standard precautions are guidelines that combine the major features of “universal precautions and body substance isolation” practices. Standard precautions cover the transmission of all known infectious agents and thus are more comprehensive than universal precautions, which are intended to apply only to transmission of bloodborne pathogens. Published